1994
Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
Longo D, Duffey P, Jaffe E, Raffeld M, Hubbard S, Fisher R, Wittes R, DeVita V, Young R. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy. Journal Of Clinical Oncology 1994, 12: 2153-9. PMID: 7523607, DOI: 10.1200/jco.1994.12.10.2153.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinCombined Modality TherapyCyclophosphamideCytarabineDisease-Free SurvivalDoxorubicinEtoposideFemaleFollow-Up StudiesHumansLymphoma, Non-HodgkinMaleMechlorethamineMethotrexateMiddle AgedPrednisoneProcarbazinePrognosisRemission InductionSurvival RateVincristineConceptsAdvanced stage diseaseProMACE-MOPPProMACE-CytaBOMBurkitt's lymphomaLocalized diseaseComplete responseInvolved-field radiation therapyCombination chemotherapy programsOverall survival rateEfficacy of cyclophosphamideTreatment of patientsHigh-grade lymphomaMedian followComplete remissionIntercurrent illnessAdult patientsChemotherapy programCombination chemotherapyOverall survivalAggressive lymphomaRadiation therapyPatientsLymphomaSurvival rateDisease
1993
CHOP versus Intensive Regimens in Non-Hodgkin's Lymphoma
Longo D, DeVita V, Young R. CHOP versus Intensive Regimens in Non-Hodgkin's Lymphoma. New England Journal Of Medicine 1993, 329: 580-582. PMID: 7687747, DOI: 10.1056/nejm199308193290817.Peer-Reviewed Original Research
1991
Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas
Fisher R, Longo D, DeVita V, Hubbard S, Miller T, Young R. Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas. Annals Of Oncology 1991, 2: 33-35. PMID: 1710487, DOI: 10.1093/annonc/2.suppl_1.33.Peer-Reviewed Original ResearchConceptsDisease-free survivalProMACE-MOPPCR rateComplete remissionProMACE-CytaBOMHodgkin's lymphomaLong-term disease-free survivalLong-term disease-free survivorsSurvival curvesStage IIDisease-free survival curvesFirst-generation regimensThird-generation regimensPhase II studyDisease-free survivorsOverall survival curvesSouthwest Oncology GroupCooperative group settingHigh-grade NHLNational Cancer InstituteSame time pointsVs 53Aggressive NHLII studyOncology GroupSuperiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
Longo D, DeVita V, Duffey P, Wesley M, Ihde D, Hubbard S, Gilliom M, Jaffe E, Cossman J, Fisher R. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. Journal Of Clinical Oncology 1991, 9: 25-38. PMID: 1702144, DOI: 10.1200/jco.1991.9.1.25.Peer-Reviewed Original ResearchConceptsDaily days 1ProMACE-MOPPComplete remissionProMACE-CytaBOMDay 1Day 8Complete respondersSmall noncleaved-cell lymphomaCo-trimoxazole prophylaxisComplete response rateDouble-strength tabletProMACE-CytaBOM regimenTreatment-related causesTreatment-related mortalityPneumocystis carinii pneumoniaDiffuse aggressive lymphomasPeriod of treatmentDay 1 treatmentCombination chemotherapyAggressive lymphomaCarinii pneumoniaMalignant lymphomaEffective treatmentPatientsResponse rate
1979
Treatment of refractory splenomegaly in myeloproliferative disease by splenic artery infusion.
Canellos G, Sutliffe S, DeVita V, Lister T. Treatment of refractory splenomegaly in myeloproliferative disease by splenic artery infusion. Blood 1979, 53: 1014-7. PMID: 435637, DOI: 10.1182/blood.v53.5.1014.bloodjournal5351014.Peer-Reviewed Original ResearchConceptsSplenic artery infusionArterial infusionBlastic phase of chronic granulocytic leukemiaRefractory to previous therapyPhase of chronic granulocytic leukemiaChronic granulocytic leukemiaResponse to treatmentBlastic phasePrevious therapyMassive splenomegalyMyeloproliferative diseaseSystemic toxicityGranulocytic leukemiaSpleen sizeSymptomatic reliefCytosine arabinosidePatientsSplenomegalyInfusionTreatmentHypersplenismPainLeukemiaTherapyArabinoside
1978
Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.
Dedrick R, Myers C, Bungay P, DeVita V. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Journal Of The National Cancer Institute 1978, 62: 1-11. PMID: 626987.Peer-Reviewed Original ResearchConceptsOvarian cancerResidual ovarian cancerTreatment of patientsPharmacokinetic rationalePlasma clearancePeritoneal cavityPeritoneal spaceDrug AdministrationPharmacokinetic calculationsPeritoneal permeabilitySuch drugsCancerAnticancer drugsDrugsTreatmentHydrophilic anticancer drugPatientsAdministrationClearance
1976
Chemotherapy of the blastic phase of chronic granulocytic leukemia: hypodiploidy and response to therapy.
Canellos G, DeVita V, Whang-Peng J, Chabner B, Schein P, Young R. Chemotherapy of the blastic phase of chronic granulocytic leukemia: hypodiploidy and response to therapy. Blood 1976, 47: 1003-9. PMID: 1064434, DOI: 10.1182/blood.v47.6.1003.bloodjournal4761003.Peer-Reviewed Original ResearchConceptsChromosome-positive chronic granulocytic leukemiaChronic granulocytic leukemiaBlastic phaseComplete remissionPrior splenectomyComplete remittersGranulocytic leukemiaCytosine arabinosidePhiladelphia chromosome-positive chronic granulocytic leukemiaNonsplenectomized groupPrednisone groupPartial remissionMedian survivalElective splenectomyPartial responseSecondary therapyChronic phaseOpposite regimenRemissionSplenectomyVincristinePrednisoneChemotherapyPatientsCell lines